Security key
31447E105
FEMASYS INC - Common Stock, par value $0.0001 per share (FEMY)
CUSIP: 31447E105
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 9,472,339
- Total 13F value
- $3,979,908
- Share change
- -144,322
- SEC-reported price per share
- $0.42
- Number of holders
- 36
- Value change
- -$150,277
- Number of buys
- 14
- Number of sells
- 15
- Shares outstanding
- 62,678,844
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
36
Top holders
10
FEMY full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
FEMASYS INC SEC filings
FEMASYS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 31447E105
Recent filing periods:
Ownership snapshot
Top reported holders of FEMY - FEMASYS INC - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alumni Capital LP
Disclosed value leader
Alumni Capital LP
Comparable rows
15/15
Latest evidence
17 Mar 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: Alumni Capital LP
Showing 1-6 of 15 holder rows.
Quick read
Alumni Capital LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alumni Capital LP's linked filing trail.
Comparable ownership
Top 5
Alumni Capital LP
10%
Dauntless Investment Group, LLC
9.9%
Jorey Chernett
9.3%
PharmaCyte Biotech, Inc.
7.9%
VANGUARD GROUP INC
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alumni Capital LP |
13D/G
|
10%
|
$3,866,599
4,773,579 shares
|
$0 | 04 Sep 2025 |
| Dauntless Investment Group, LLC |
13D/G
13F
Company
|
9.9%
|
$1,549,149
4,395,996 shares
|
+$1,045,272 | 30 Sep 2025 |
| Jorey Chernett |
13D/G
Chernett Jorey
|
9.3%
|
$2,930,561
3,034,335 shares
|
+$1,361,799 | 30 Jun 2025 |
| PharmaCyte Biotech, Inc. |
13D/G
|
7.9%
|
$2,762,382
4,932,825 shares
|
$0 | 17 Mar 2026 |
| VANGUARD GROUP INC |
13F
Company
|
2.3%
|
$815,360
1,415,555 shares
|
— | 31 Dec 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.62%
|
$224,326
389,280 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
36
Shares
9,472,339
Rows available
36
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
37
Q1 2026 holders
36
Holder diff
-1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend